Evidence map›Paper›PMID 32061622›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Glutathione-responsive biodegradable polyurethane nanoparticles for lung cancer treatment.

Roshni Iyer, Tam Nguyen, Dona Padanilam, Cancan Xu, Debabrata Saha, Kytai T Nguyen, Yi Hong

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Roshni IyerDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Tam NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Dona PadanilamDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Cancan XuDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Debabrata SahaDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Kytai T NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: knguyen@uta.edu.
Yi HongDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: yihong@uta.edu.
The University of Texas at Arlington · USThe University of Texas Southwestern Medical Center · US

Funding

Interdisciplinary Training in Nanotechnology for Cardiovascular and Lung Diseases in North TexasT32HL134613 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG · 2017 to 2021
$1.1M
NHLBI NIH HHS T32 HL134613
6 · The paper itself

Abstract

Lung cancer is one of the major causes of cancer-related deaths worldwide. Stimuli-responsive polymers and nanoparticles, which respond to exogenous or endogenous stimuli in the tumor microenvironment, have been widely investigated for spatiotemporal chemotherapeutic drug release applications for cancer chemotherapy. We developed glutathione (GSH)-responsive polyurethane nanoparticles (GPUs) using a GSH-cleavable disulfide bond containing polyurethane that responds to elevated levels of GSH within lung cancer cells. The polyurethane nanoparticles were fabricated using a single emulsion and mixed organic solvent method. Cisplatin-loaded GSH-sensitive nanoparticles (CGPU) displayed a GSH-dose dependent release of cisplatin. In addition, a significant reduction in in vitro survival fraction of A549 lung cancer cells was observed compared to free cisplatin of equivalent concentration (survival fraction of ~0.5 and ~0.7, respectively). The in vivo biodistribution studies showed localization of fluorescently labeled GPUs (~7% of total injected dose per gram tissue) in the lung tumor regions after mouse-tail IV injections in xenograft A549 lung tumor models. The animals exposed to CGPUs also exhibited the inhibition of lung tumor growth compared to animals administered with saline (tumor growth rate of 1.5 vs. 13 in saline) and free cisplatin (tumor growth rate of 5.9) in mouse xenograft A549 lung tumor models within 14 days. These nanoparticles have potential to be used for on-demand drug release for an enhanced chemotherapy to effectively treat lung cancer.

Indexed as

Antineoplastic AgentsDrug CarriersGlutathioneLung NeoplasmsNanoparticlesAnimalsCell Line, TumorCisplatinMicePolyurethanesTissue DistributionTumor MicroenvironmentAntineoplastic AgentsCisplatinDrug CarriersGlutathionePolyurethanesCisplatinGlutathioneLung cancerNanoparticlesStimuli responsive

Identifiers

PMID32061622
PMCPMC7238739
OpenAlexW3005697872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.